Value
8.6/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 8.1 |
| Analyst target | 9.0 |
- ▸Attractively valued
PACB · Why this verdict
Why Pacific Biosciences of Californ (PACB) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.6/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Quality sits at 2.8, below the engine's 4.0 floor, driven by cash burn of -30% of revenue and the absence of a competitive moat. Quality breakdown | FCF as a percentage of revenue should improve to better than -15% and quality score should rise above 4.0 over the next 12 months. | →Stable |
| CounterA genomics-sequencing hardware company burning cash at this rate may need dilutive financing before profitability improves, worsening rather than resolving the quality gap. | ||
The company has beaten consensus EPS estimates in all of the last 4 quarters, with an average surprise of roughly 14%. Catalyst breakdown | The beat streak should continue for at least 3 of the next 4 quarters. | →Stable |
| CounterConsistent beats against a backdrop of heavy cash burn and no moat could reflect deliberately conservative guidance rather than genuine operating improvement. | ||
Analysts see 46% upside to target, though coverage is light (6 analysts), which the model flags as a dampened signal. Sentiment breakdown | Analyst price targets should hold or rise, and coverage breadth should increase, over the next 12 months. | →Stable |
| CounterLight analyst coverage means the 46% upside figure rests on a small sample and could be revised sharply if even one analyst downgrades. | ||
Short interest of 22% and implied volatility of 135% point to significant bearish positioning and expected price swings. Key risks | Short interest should decline below 15% and implied volatility should moderate below 100% over the next 12 months. | →Stable |
| CounterExtremely high short interest combined with a strong earnings beat streak could instead set up a short squeeze rather than confirming the bearish thesis. | ||
The stock trades below its 200-day moving average, but that average is still rising (+1.4% over 30 days), consistent with a pullback within an uptrend. Momentum breakdown | Price should reclaim the 200-day moving average within 12 months while the average continues to trend up. | →Stable |
| CounterA rising average with price below it can also mark the early stage of a downtrend, especially for a cash-burning company with no moat. | ||
Quality sits at 2.8, below the engine's 4.0 floor, driven by cash burn of -30% of revenue and the absence of a competitive moat.
→StableQuality breakdown
- Expectation
- FCF as a percentage of revenue should improve to better than -15% and quality score should rise above 4.0 over the next 12 months.
CounterA genomics-sequencing hardware company burning cash at this rate may need dilutive financing before profitability improves, worsening rather than resolving the quality gap.
The company has beaten consensus EPS estimates in all of the last 4 quarters, with an average surprise of roughly 14%.
→StableCatalyst breakdown
- Expectation
- The beat streak should continue for at least 3 of the next 4 quarters.
CounterConsistent beats against a backdrop of heavy cash burn and no moat could reflect deliberately conservative guidance rather than genuine operating improvement.
Analysts see 46% upside to target, though coverage is light (6 analysts), which the model flags as a dampened signal.
→StableSentiment breakdown
- Expectation
- Analyst price targets should hold or rise, and coverage breadth should increase, over the next 12 months.
CounterLight analyst coverage means the 46% upside figure rests on a small sample and could be revised sharply if even one analyst downgrades.
Short interest of 22% and implied volatility of 135% point to significant bearish positioning and expected price swings.
→StableKey risks
- Expectation
- Short interest should decline below 15% and implied volatility should moderate below 100% over the next 12 months.
CounterExtremely high short interest combined with a strong earnings beat streak could instead set up a short squeeze rather than confirming the bearish thesis.
The stock trades below its 200-day moving average, but that average is still rising (+1.4% over 30 days), consistent with a pullback within an uptrend.
→StableMomentum breakdown
- Expectation
- Price should reclaim the 200-day moving average within 12 months while the average continues to trend up.
CounterA rising average with price below it can also mark the early stage of a downtrend, especially for a cash-burning company with no moat.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Pacific Biosciences shows a perfect recent earnings beat streak and analyst-projected upside, but persistent cash burn below the quality floor and heavy bearish positioning in a volatile stock temper the case for near-term conviction.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
2.8/10data confidence 100%| Component | Sub-score |
|---|---|
| ROA | 0.0 |
| Gross margin | 3.7 |
| Net margin | 0.0 |
| Current ratio | 7.3 |
| FCF quality | 0.0 |
| Moat | 3.9 |
| Piotroski F | 4.4 |
- ▸Cash-burning: FCF -30% of revenue
- ▸No competitive moat
- ▸Quality concerns
Growth
2.5/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 2.5 |
Momentum
6.0/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.0 |
| MACD | 7.3 |
| OBV | 10.0 |
| MA position | 7.2 |
| Volume | 2.3 |
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA but MA still rising (+1.4%/30d) — pullback in uptrend, not confirmed weakness
Sentiment
7.2/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 6.6 |
| Price target | 9.4 |
| erm sentiment | 5.5 |
- ▸Light analyst coverage (6.0) — signal dampened
- ▸Analyst upside: 46%
Insider
5.0/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.1 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
Peer rank
1.3/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 4.4 |
| quality rank | 0.0 |
| growth rank | 1.0 |
Technical
2.3/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.7 |
| support resistance | 2.8 |
| 52w position | 2.3 |
Risk (lower is worse)
1.7/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 1.3 |
| days to cover | 0.0 |
| volatility | 0.0 |
| put call | 8.3 |
| implied vol | 0.0 |
| beta | 2.4 |
| debt equity | 0.0 |
- ▸High short interest justified: 22%
- ▸High IV: 147%
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
7.4/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 9.5 |
- ▸Perfect beat streak: 4Q
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (7)
- MOMENTUM:6.0>=5.5
- ASYMMETRY:1.8>=1.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:32d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (1)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
1.82
Upside
+27.3%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeInst Constrain — Small cap ($0.5B) below institutional reach
SuitabilityAggressive — Beta 2.29>1.3, MCap $0.5B<$5B
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Value at 8.6 could not lift the engine output above the verdict floor.
The strongest dimensions are Value at 8.6, Catalyst at 7.4, and Sentiment at 7.2; the weakest are Peer rank at 1.3, Risk (lower is worse) at 1.7, and Technical at 2.3. The V9 engine cleared all gates with 1 warning, producing an asymmetric reward-to-risk of 1.82 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Cash Burn Quality Floor Breach
Trip ifFCF as a percentage of revenue falls below -40%.
- P2Perfect Earnings Beat Streak
Trip ifEPS surprise stays below 0% for 2 consecutive quarters.
- P3Analyst Upside Despite Light Coverage
Trip ifAverage analyst price target falls by more than 20%.
- P4High Short Interest Elevated Iv
Trip ifShort interest rises above 35% of float.
- P5Pullback In Rising Trend
Trip ifPrice falls more than 15% below the 200-day moving average.